Int J Endocrinol (2020) 2020:1484321
34 The AHA guidelines endorse GLP-1 RAs, including semaglutide and liraglutide, because these medications have shown significant benefits in reducing major adverse cardiovascular events (MACE) and heart failure exacerbations, as demonstrated in the LEADER and SUSTAIN-6 trials (Table 3)
What This GLP-1 Cluster Explains Across this series, youll learn: how GLP-1 works within enteroendocrine and gutbrain signaling why microbiome damage weakens GLP-1 sensitivity how stress and cortisol disrupt appetite regulation how SCFAs restore metabolic flexibility what GLP-1 medications cannot biologically repair Whether GLP-1 medications are used or not, long-term metabolic outcomes depend on the same foundation : A stable microbiome that produces adequate SCFAs and supports natural GLP-1 signaling
Image Credit: Tatjana Baibakova/Shutteratock
Lee MJ, Koff JL, Hildebrandt MAT , Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave SP, Dave SS, Flowers CR